High‐molecular‐weight β‐amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients

Clinical diagnosis of Alzheimer's disease: Report of the NINCDS‐ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915 · see citing works

The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics

Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864 · see citing works

Diagnostic and Statistical Manual of Mental Disorders

&NA; (1988) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-198802020-00022 · Cited by 12,603 · see citing works

Mild Cognitive Impairment: Clinical Characterization and Outcome

Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999) · Archives of Neurology · doi:10.1001/archneur.56.3.303 · Cited by 8,980 · see citing works

Mild cognitive impairment as a diagnostic entity

Petersen, R. C. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01388.x · Cited by 7,864 · see citing works

Alzheimer's disease: the amyloid cascade hypothesis

Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484 · see citing works

Diagnostic and Statistical Manual of Mental Disorders, 3rd ed

Cooper, A. M., & Michels, R. (1981) · American Journal of Psychiatry · doi:10.1176/ajp.138.1.128 · Cited by 7,417 · see citing works

Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo

Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291 · see citing works

Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis

Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., & Glabe, C. G. (2003) · Science · doi:10.1126/science.1079469 · Cited by 4,064 · see citing works

Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory

Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685 · see citing works

Diffusible, nonfibrillar ligands derived from Aβ _1–42 are potent central nervous system neurotoxins

Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506 · see citing works

The carboxy terminus of the .beta. amyloid protein is critical for the seeding of amyloid formation: Implications for the pathogenesis of Alzheimer's disease

Jarrett, J. T., Berger, E. P., & Lansbury, P. T. (1993) · Biochemistry · doi:10.1021/bi00069a001 · Cited by 2,022 · see citing works

Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals: Evidence that an initially deposited species is Aβ42(43)

Iwatsubo, T., Odaka, A., Suzuki, N., Mizusawa, H., Nukina, N., & Ihara, Y. (1994) · Neuron · doi:10.1016/0896-6273(94)90458-8 · Cited by 1,774 · see citing works

Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution

Stefani, M., & Dobson, C. M. (2003) · Journal of Molecular Medicine · doi:10.1007/s00109-003-0464-5 · Cited by 1,643 · see citing works

An Increased Percentage of Long Amyloid β Protein Secreted by Familial Amyloid β Protein Precursor (βApp ₇₁₇ ) Mutants

Suzuki, N., Cheung, T. T., Cai, X.-D., Odaka, A., Otvos, L., Eckman, C., Golde, T. E., & Younkin, S. G. (1994) · Science · doi:10.1126/science.8191290 · Cited by 1,471 · see citing works

Oligomeric and fibrillar species of amyloid-β peptides differentially affect neuronal viability

Dahlgren, K. N., Manelli, A. M., Stine, W. B., Baker, L. K., Krafft, G. A., & LaDu, M. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m201750200 · Cited by 1,452 · see citing works

CSF markers for incipient Alzheimer's disease

Blennow, K., & Hampel, H. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00530-1 · Cited by 1,291 · see citing works

Targeting small Aβ oligomers: the solution to an Alzheimer's disease conundrum?

Klein, W. (2001) · Trends in Neurosciences · doi:10.1016/s0166-2236(00)01749-5 · Cited by 989 · see citing works

Amyloid-β protein oligomerization and the importance of tetramers and dodecamers in the aetiology of Alzheimer’s disease

Bernstein, S. L., Dupuis, N., Lazo, N., Wyttenbach, T., Condron, M., Bitan, G., Teplow, D., Shea, J., Ruotolo, B., Robinson, C., et al. (2009) · Nature Chemistry · doi:10.1038/nchem.247 · Cited by 847 · see citing works

Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer’s disease

Georganopoulou, D. G., Chang, L., Nam, J.-M., Thaxton, C. S., Mufson, E. J., Klein, W. L., & Mirkin, C. A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409336102 · Cited by 835 · see citing works

Normal and Abnormal Biology of the Beta-Amyloid Precursor Protein

Selkoe, D. J. (1994) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.17.030194.002421 · Cited by 827 · see citing works

Structure–neurotoxicity relationships of amyloid β-protein oligomers

Ono, K., Condron, M. M., & Teplow, D. B. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905127106 · Cited by 774 · see citing works

Alzheimer's Disease: A Central Role for Amyloid

Selkoe, D. J. (1994) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-199409000-00003 · Cited by 752 · see citing works

Tau protein and the neurofibrillary pathology of Alzheimer's disease

Goedert, M. (1993) · Trends in Neurosciences · doi:10.1016/0166-2236(93)90078-z · Cited by 718 · see citing works

Reduction of β‐amyloid peptide₄₂ in the cerebrospinal fluid of patients with Alzheimer's disease

Motter, R., Vigo‐Pelfrey, C., Kholodenko, D., Barbour, R., Johnson‐Wood, K., Galasko, D., Chang, L., Miller, B., Clark, C., Green, R., et al. (1995) · Annals of Neurology · doi:10.1002/ana.410380413 · Cited by 701 · see citing works

A century-old debate on protein aggregation and neurodegeneration enters the clinic

Lansbury, P. T., & Lashuel, H. A. (2006) · Nature · doi:10.1038/nature05290 · Cited by 681 · see citing works

Decreased β-Amyloid_1-42and Increased Tau Levels in Cerebrospinal Fluid of Patients With Alzheimer Disease

Sunderland, T., Linker, G., Mirza, N., Putnam, K. T., Friedman, D. L., Kimmel, L. H., Bergeson, J., Manetti, G. J., Zimmermann, M., Tang, B., et al. (2003) · JAMA · doi:10.1001/jama.289.16.2094 · Cited by 656 · see citing works

Globular amyloid β‐peptide ₁₋₄₂ oligomer − a homogenous and stable neuropathological protein in Alzheimer's disease

Barghorn, S., Nimmrich, V., Striebinger, A., Krantz, C., Keller, P., Janson, B., Bahr, M., Schmidt, M., Bitner, R. S., Harlan, J., et al. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03407.x · Cited by 559 · see citing works

Longitudinal study of cerebrospinal fluid levels of tau, Aβ1–40, and Aβ1–42(43) in Alzheimer's disease: A study in Japan

Kanai, M., Matsubara, E., Isoe, K., Urakami, K., Nakashima, K., Arai, H., Sasaki, H., Abe, K., Iwatsubo, T., Kosaka, T., et al. (1998) · Annals of Neurology · doi:10.1002/ana.410440108 · Cited by 340 · see citing works

Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics

Shaw, L. M. J., Korecka, M., Clark, C. M., Lee, V. M. ‐., & Trojanowski, J. Q. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2176 · Cited by 339 · see citing works

Neurochemical diagnosis of Alzheimer’s dementia by CSF Aβ42, Aβ42/Aβ40 ratio and total tau

Lewczuk, P., Esselmann, H., Otto, M., Maler, J. M., Henkel, A. W., Henkel, M. K., Eikenberg, O., Antz, C., Krause, W., Reulbach, U., et al. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(03)00086-1 · Cited by 309 · see citing works

Sensitive ELISA detection of amyloid‐β protofibrils in biological samples

Englund, H., Sehlin, D., Johansson, A., Nilsson, L. N. G., Gellerfors, P., Paulie, S., Lannfelt, L., & Pettersson, F. E. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04759.x · Cited by 292 · see citing works

Fluctuations of CSF amyloid-β levels: Implications for a diagnostic and therapeutic biomarker

Bateman, R. J., Wen, G., Morris, J. C., & Holtzman, D. M. (2007) · Neurology · doi:10.1212/01.wnl.0000256043.50901.e3 · Cited by 260 · see citing works

Age but Not Diagnosis Is the Main Predictor of Plasma Amyloid β-Protein Levels

Fukumoto, H., Tennis, M. K., Locascio, J. J., Hyman, B. T., Growdon, J. H., & Irizarry, M. C. (2003) · Archives of Neurology · doi:10.1001/archneur.60.7.958 · Cited by 258 · see citing works

Targeting Amyloid-β Peptide (Aβ) Oligomers by Passive Immunization with a Conformation-selective Monoclonal Antibody Improves Learning and Memory in Aβ Precursor Protein (APP) Transgenic Mice

Lee, E. B., Leng, L. Z., Zhang, B., Kwong, L. K., Trojanowski, J. Q., Abel, T. G., & Lee, V. M. ‐. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m511018200 · Cited by 252 · see citing works

A Specific Enzyme-Linked Immunosorbent Assay for Measuring β-Amyloid Protein Oligomers in Human Plasma and Brain Tissue of Patients With Alzheimer Disease

Xia, W., Yang, T., Shankar, G. M., Smith, I. M., Shen, Y., Walsh, D. M., & Selkoe, D. J. (2009) · Archives of Neurology · doi:10.1001/archneurol.2008.565 · Cited by 215 · see citing works

Oligomerization and Toxicity of β-Amyloid-42 Implicated in Alzheimer's Disease

El‐Agnaf, O. M. A., Mahil, D. S., PATEL, B. P., & Austen, B. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.3051 · Cited by 196 · see citing works

Inhibition of fibril formation in beta-amyloid peptide by a novel series of benzofurans.

Howlett, D. R., Perry, A. E., GODFREY, F., et al. (1999) · PubMed · Cited by 180 · see citing works

Fractionation and characterization of oligomeric, protofibrillar and fibrillar forms of β-amyloid peptide

Ward, R. V., JENNINGS, K. H., Jepras, R., Neville, W. A., OWEN, D. E., HAWKINS, J., Christie, G., Davis, J. B., George, A. R., Karran, E. H., et al. (2000) · Biochemical Journal · doi:10.1042/bj3480137 · Cited by 153 · see citing works

Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease

Galasko, D. R., Clark, C., Chang, L., Miller, B. L., Green, R. C., Motter, R. N., & Seubert, P. A. (1997) · Neurology · doi:10.1212/wnl.48.3.632 · Cited by 153 · see citing works

Long Amyloid .beta.-Protein Secreted from Wild-Type Human Neuroblastoma IMR-32 Cells

Asami-Odaka, A., Ishibashi, Y., Kikuchi, T., Kitada, C., & Suzuki, N. (1995) · Biochemistry · doi:10.1021/bi00032a022 · Cited by 147 · see citing works

Amyloid β protein 42(43) in cerebrospinal fluid of patients with Alzheimer's disease

Tamaoka, A., Sawamura, N., Fukushima, T., Shoji, S., Matsubara, E., Shoji, M., Hirai, S., Furiya, Y., Endoh, R., & Mori, H. (1997) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(96)00314-0 · Cited by 139 · see citing works

Alzheimer’s β-peptide oligomer formation at physiologic concentrations

LeVine, H. (2004) · Analytical Biochemistry · doi:10.1016/j.ab.2004.08.014 · Cited by 123 · see citing works

Inhibition of fibril formation in β-amyloid peptide by a novel series of benzofurans

Howlett, D. R., PERRY, A. E., GODFREY, F., et al. (1999) · Biochemical Journal · doi:10.1042/bj3400283 · Cited by 112 · see citing works

Genetic studies of human apolipoproteins. V. A novel rapid procedure to screen apolipoprotein E polymorphism

Kamboh, M. I., Ferrell, R. E., & Kottke, B. A. (1988) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)38431-5 · Cited by 103 · see citing works

Plasma Levels of amyloid β proteins Aβ1–40 and Aβ1–42(43) are elevated in Down's syndrome

Tokuda, T., Fukushima, T., Ikeda, S., Sekijima, Y., Shoji, S., Yanagisawa, N., & Tamaoka, A. (1997) · Annals of Neurology · doi:10.1002/ana.410410220 · Cited by 92 · see citing works

Primary cultures of neuronal and non-neuronal rat brain cells secrete similar proportions of amyloid β peptides ending at Aβ40 and Aβ42

Fukumoto, H., Tomita, T., Matsunaga, H., Ishibashi, Y., Saido, T. C., & Iwatsubo, T. (1999) · Neuroreport · doi:10.1097/00001756-199909290-00017 · Cited by 61 · see citing works

Soluble oligomers for the diagnosis of neurodegenerative diseases

El‐Agnaf, O. M. A., Walsh, D. M., & Allsop, D. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00481-2 · Cited by 50 · see citing works

Characterisation of two antibodies to oligomeric Aβ and their use in ELISAs on human brain tissue homogenates

Helmond, Z. V., Heesom, K. J., & Love, S. (2008) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2008.09.002 · Cited by 44 · see citing works

Inhibition of fibril formation in β-amyloid peptide by a novel series of benzofurans

Howlett, D. R., PERRY, A. E., GODFREY, F., et al. (1999) · Biochemical Journal · doi:10.1042/0264-6021:3400283 · Cited by 42 · see citing works

Prednisolone (30–60 mg/day) for diseases other than AD decreases amyloid β-peptides in CSF

Tokuda, T., Oide, T., Tamaoka, A., et al. (2002) · Neurology · doi:10.1212/wnl.58.9.1415 · Cited by 14 · see citing works

The Amyloid-β Pathway in Alzheimer’s Disease

Hampel, H., Hardy, J., Blennow, K., Chen, C., Perry, G., Kim, S. H., Villemagne, V. L., Aisen, P., Vendruscolo, M., Iwatsubo, T., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01249-0 · Cited by 1,952 · see citing works

The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease

Ferreira, S. T., & Klein, W. L. (2011) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2011.08.003 · Cited by 442 · see citing works

Soluble amyloid-β oligomers as synaptotoxins leading to cognitive impairment in Alzheimer’s disease

Ferreira, S. T., Lourenco, M. V., Oliveira, M. M., & De Felice, F. G. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00191 · Cited by 373 · see citing works

Role of Amyloid-β and Tau Proteins in Alzheimer’s Disease: Confuting the Amyloid Cascade

Gulisano, W., Maugeri, D., Baltrons, M. A., Fà, M., Amato, A., Palmeri, A., D’Adamio, L., Grassi, C., Devanand, D. P., Honig, L. S., et al. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-179935 · Cited by 313 · see citing works

The path forward in Alzheimer's disease therapeutics: Reevaluating the amyloid cascade hypothesis

Tolar, M., Abushakra, S., & Sabbagh, M. (2020) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.09.075 · Cited by 275 · see citing works

Amyloid β-protein oligomers and Alzheimer’s disease

Hayden, E. Y., & Teplow, D. B. (2013) · Alzheimer's Research & Therapy · doi:10.1186/alzrt226 · Cited by 276 · see citing works

Bivalent Brain Shuttle Increases Antibody Uptake by Monovalent Binding to the Transferrin Receptor

Hultqvist, G., Syvänen, S., Fang, X. T., Lannfelt, L., & Sehlin, D. (2017) · Theranostics · doi:10.7150/thno.17155 · Cited by 224 · see citing works

Soluble Aβ Oligomers Are Rapidly Sequestered from Brain ISF In Vivo and Bind GM1 Ganglioside on Cellular Membranes

Hong, S., Ostaszewski, B. L., Yang, T., O’Malley, T. T., Jin, M., Yanagisawa, K., Li, S., Bartels, T., & Selkoe, D. J. (2014) · Neuron · doi:10.1016/j.neuron.2014.02.027 · Cited by 213 · see citing works

Fluid Biomarkers in Alzheimer Disease

Blennow, K., Zetterberg, H., & Fagan, A. M. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006221 · Cited by 208 · see citing works

Multi-Target-Directed Ligands and other Therapeutic Strategies in the Search of a Real Solution for Alzheimer’s Disease

Agis-Torres, A., Sollhuber, M., Fernandez, M., & Sanchez-Montero, J. M. (2014) · Current Neuropharmacology · doi:10.2174/1570159x113116660047 · Cited by 202 · see citing works

Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer’s disease immunotherapeutics

Goure, W. F., Krafft, G. A., Jerecic, J., & Hefti, F. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt272 · Cited by 190 · see citing works

The keystone of Alzheimer pathogenesis might be sought in Aβ physiology

Puzzo, D., Gulisano, W., Arancio, O., & Palmeri, A. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.08.039 · Cited by 116 · see citing works

Aβ40 Oligomers Identified as a Potential Biomarker for the Diagnosis of Alzheimer's Disease

Gao, C. M., Yam, A. Y., Wang, X., Magdangal, E., Salisbury, C., Peretz, D., Zuckermann, R. N., Connolly, M. D., Hansson, O., Minthon, L., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015725 · Cited by 105 · see citing works

Identification of Low Molecular Weight Pyroglutamate Aβ Oligomers in Alzheimer Disease

Wirths, O., Erck, C., Martens, H., Harmeier, A., Geumann, C., Jawhar, S., Kumar, S., Multhaup, G., Walter, J., Ingelsson, M., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.178707 · Cited by 103 · see citing works

Hippocampal GABAergic Neurons are Susceptible to Amyloid-β Toxicity in vitro and are Decreased in Number in the Alzheimer's Disease TgCRND8 Mouse Model

Krantic, S., Isorce, N., Mechawar, N., Davoli, M. A., Vignault, E., Albuquerque, M., Chabot, J.-G., Moyse, E., Chauvin, J.-P., Aubert, I., et al. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-110830 · Cited by 78 · see citing works

Amyloid-β Oligomers Relate to Cognitive Decline in Alzheimer's Disease

Jongbloed, W., Bruggink, K. A., Kester, M. I., Visser, P.-J., Scheltens, P., Blankenstein, M. A., Verbeek, M. M., Teunissen, C. E., & Veerhuis, R. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-142136 · Cited by 68 · see citing works

Immunomodulation targeting of both Aβ and tau pathological conformers ameliorates Alzheimer’s disease pathology in TgSwDI and 3xTg mouse models

Goñi, F., Herline, K., Peyser, D., Wong, K., Ji, Y., Sun, Y., Mehta, P., & Wisniewski, T. (2013) · Journal of Neuroinflammation · doi:10.1186/1742-2094-10-150 · Cited by 43 · see citing works

Fluorescent peptide nanoparticles to detect amyloid-beta aggregation in cerebrospinal fluid and serum for Alzheimer’s disease diagnosis and progression monitoring

Sun, L., Liu, D., Fu, D., Yue, T., Scharre, D., & Zhang, L. (2021) · Chemical Engineering Journal · doi:10.1016/j.cej.2020.126733 · Cited by 32 · see citing works

Alzheimer's disease biomarkers: correspondence between human studies and animal models

Sabbagh, J. J., Kinney, J. W., & Cummings, J. L. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.04.010 · Cited by 27 · see citing works

A case report of pulmonary amyloidosis recognized by detection of AA amyloid exclusively in alveolar macrophages

Laohawetwanit, T., Tanaka, K., Zaizen, Y., et al. (2020) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2020.101046 · Cited by 2 · see citing works

[Localized primary cutaneous nodular amyloidosis].

Ferrara, G., Cusano, F., Capozzi, M., et al. (1992) · PubMed

Concentrations of amyloid β protein in cerebrospinal fluid of patients with alzheimer's disease

van Gool, W. A., Walstra, G. J. M., Bolhuis, P. A., Kuiper, M. A., & Wolters, E. C. (1995) · Annals of Neurology · doi:10.1002/ana.410370221 · Cited by 82 · see citing works

Novel photocatalytic carbon dots: efficiently inhibiting amyloid aggregation and quickly disaggregating amyloid aggregates

Shao, X., Wang, C., Wang, C., Bai, M., Hou, T., Wang, X., Yan, C., Guan, P., & Hu, X. (2024) · Nanoscale · doi:10.1039/d3nr06165e · Cited by 17 · see citing works

Pitfalls in the quantitative estimation of β-amyloid immunoreactivity in human brain tissue

Kraszpulski, M., Soininen, H. S., Riekkinen, P. J., & Alafuzoff, I. I. (1998) · Histochemistry and Cell Biology · doi:10.1007/s004180050305 · Cited by 15 · see citing works